In a statement, Novo Nordisk acknowledged the importance of access to these treatments but emphasized the complexities involved in drug development, production, and healthcare systems. The company expressed a commitment to working with policymakers to improve affordability, a position reiterated in their discussion with Sanders. The investigation aims to clarify Novo Nordisk’s internal decision-making process, profit margins, and pricing rationale. Sanders has requested the company to provide substantial price reductions for both Ozempic and Wegovy to ensure accessibility for all patients who need them. The high prices of these medications have raised concerns about their affordability for millions of Americans, particularly those covered by Medicare and Medicaid. Sanders warned that these costs could jeopardize the sustainability of these key programs unless addressed promptly.
Sen. Bernie Sanders Launches Probe into High Prices of Novo Nordisk Diabetes and Weight Loss Drugs
